Acute lymphoblastic leukemia (ALL) is the most common childhood cancer and has excellent survival rates. However, outcomes for patients who relapse are poor and ALL remains one of the major causes of childhood cancer death. Over the past decade there have been major advances in understanding the genomic landscape of childhood ALL and in developing new precision medicine therapies and immunotherapies. Dr. Hunger will summarize current understanding of childhood ALL and talk about new therapies that are highly active in relapsed and refractory ALL and are now being tested in newly diagnosed ALL.
- Understand genetic and treatment response risk factors in ALL
- Learn about immunotherapies that are active in relapsed and refractory ALL, including blinatumomab, inotuzumab and chimeric antigen receptor (CAR) T-cells.
- Learn about new clinical trials testing these immunotherapies in childhood ALL.
ACCME Accreditation Statement: Children’s Hospital of Philadelphia is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA Credit Designation Statement: Children's Hospital of Philadelphia designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Sarah Tasian, MD (Moderator), Katie Lockwood, MD (CHOP Talks Course Director) and Monica S. Williams (CME Planner) and others as appropriate have no relevant financial relationship with a commercial interest to disclose.
Stephen Hunger, MD (Speaker) has a relevant financial relationship that has been mitigated though the CHOP CME Mitigation Process.
Related specialties: oncology, hematology, genetics, general pediatrics